Weight Gain Concerns: Eli Lilly's Obesity Drug Users Experience Regained Weight After Quitting

Eli Lilly shares dropped 2.3% after a study revealed that patients who use its weight-loss treatments may experience weight gain once they stop taking the drugs. The study focused on Zepbound, a recently FDA-approved drug for obesity and overweight patients. Those who continued taking Zepbound experienced additional weight loss, while those given a placebo saw their weight increase. The findings highlight the importance of ongoing treatment for obesity as a chronic disease. The active ingredient in Zepbound, tirzepatide, is also present in Lilly's popular weight loss and diabetes medicine, Mounjaro.